Novartis, the International pharmaceutical major, headquartered in Switzerland has shown a keen interest in cancer treatment.
To this end, the company has recently acquired Admune Therapeutics, and entered exclusive licensing agreements with other small companies like Xoma, Palobofarma to develop and use their TGF-beta inhibition program and adenosine receptor respetively in Novartis’ immuno-oncology portfolio.
All these activities are giving the world’s largest pharmaceutical major in terms of revenue a dominant place in cancer immunotherapy.
